Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
https://app.periodikos.com.br/journal/medjpps/article/doi/10.5281/zenodo.10373051

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

Case report

Toenail fungal infection: a case report

Majedul Hoque

Downloads: 1
Views: 136

Abstract

Fungal infection of the nails (onychomycosis) is a common condition that is hard to cure. The fungus hidden in the nail is difficult to treat with antifungal medications, and infected nails take months to heal. Antifungal nail polish can occasionally be used to treat mild cases, but blood-stream-permeable medications are required to treat more serious infections. We need something better because even these are not always successful and can have negative side effects like skin rash or liver issues. Additionally, onycholysis (the separation of the nail plate) creates a moist environment that can encourage the growth of fungi. Moreover, immunosuppressive medication use may worsen onychomycosis. In this example, the diseased entity's clinical presentation in an adult patient was described.

Keywords

Fungal, nail infection, toe 

References

  1. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P, Odom R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-de-Leon GF, Ghannoum A, Elewski B (2000) A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. Journal of the American Academy of Dermatology. 43 (4): 641-648. doi.org/10.1067/mjd.2000.107754
  2. Faergemann J, Baran R (2003) Epidemiology, clinical presentation and diagnosis of onychomycosis. The British Journal of Dermatology. 149 (65): 1-4. doi: 10.1046/j.1365-2133.149.s65.4.x
  3. Tosti A, Hay R, Arenas-Guzmán R (2005) Patients at risk of onychomycosis-risk factor identification and active prevention. Journal of the European Academy of Dermatology and Venereology. 19 (1): 13-16. doi: 10.1111/j. 1468-3083.2005.01282.x
  4. Szepietowski JC, Salomon J (2007) Do fungi play a role in psoriatic nails? Mycoses. 50 (6): 437-442. doi: 10.1111/j.1439-0507.2007.01405.x
  5. Tsentemeidou A, Vyzantiadis TA, Kyriakou A, Sotiriadis D, Patsatsi A (2017) Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: Results of a pilot study. Mycoses. 60 (12): 830-835. doi: 10.1111/myc.12681
  6. Rigopoulos D, Papanagiotou V, Daniel 3rd R, Piraccini BM (2017) Onychomycosis in patients with nail psoriasis: a point to point discussion. Mycoses. 60 (1): 6-10. doi: 10.1111/myc.12542
  7. de Berker D (2009) Clinical practice. Fungal nail disease. The New England Journal of Medicine. 360 (20): 2108-2116. doi: 10.1056/NEJMcp0804878
  8. Hoque M (2023) Prevalence of renal disease in Bangladesh. International Journal of Research (IJR) 10: 09. doi: 10.5281/zenodo.8338909
  9. Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC (2014) The prevalence of onychomycosis in psoriatic patients: A systematic review. Journal of European Academy of Dermatology and Venereology. 28 (5): 533-541. doi: 10.1111/jdv.12239
  10. Rizzo D, Alaimo R, Tilotta G, Dinotta F, Bongiorno MR (2013) Incidence of onychomycosis among psoriatic patients with nail involvement: a descriptive study. Mycoses. 56 (4): 498-499. doi: 10.1111/myc.12042
  11. Kaçar N, Ergin S, Ergin C, Erdogan BS, Kaleli I (2007) The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: a prospective controlled trial. Clinical and Experimental Dermatology. 32 (1): 1-5. doi: 10.1111/j.1365-2230.2006.02215.x
  12. Gupta AK, Daigle D, Foley KA (2015) The prevalence of culture-confirmed toenail onychomycosis in at-risk patient populations. Journal of European Academy of Dermatology and Venereology. 29 (6): 1039-1044. doi: 10.1111/jdv.12873
  13. Romaszkiewicz A, Bykowska B, Zabłotna M, Sobjanek M, Sławinska M, Nowicki RJ (2018) The prevalence and etiological factors of onychomycosis in psoriatic patients. Postepy Dermatologii i Alergologii. 35 (3): 309-313. doi: 10.5114/pdia.2017.68299

Submitted date:
11/30/2023

Reviewed date:
12/14/2023

Accepted date:
12/14/2023

Publication date:
12/13/2023

657a3720a9539516dd13d413 medjpps Articles
Links & Downloads

Mediterr J Pharm Pharm Sci

Share this page
Page Sections